Replies to post #124094 on Biotech Values

[masterlongevity]

bapineuzumab has significantly greater biomarker results than any other AD product

[genisi]

ElND005 is a bunch of magic beans.

Phase II data of ELND005 in mild to moderate AD were published in Neurology. In the overall population, trial did not meet its primary efficacy endpoints. In the pre-specified mild AD subgroup (MMSE scores 23-26) there were "encouraging trends":

http://www.transitiontherapeutics.com/media/news.php